Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
Reads0
Chats0
TLDR
A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.Abstract:
Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.read more
Citations
More filters
Journal ArticleDOI
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung,Jacques Ferlay,Rebecca L. Siegel,Mathieu Laversanne,Isabelle Soerjomataram,Ahmedin Jemal,Freddie Bray +6 more
TL;DR: The GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC) as mentioned in this paper show that female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung cancer, colorectal (11 4.4%), liver (8.3%), stomach (7.7%) and female breast (6.9%), and cervical cancer (5.6%) cancers.
Journal ArticleDOI
Cancer statistics in China, 2015
Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He +8 more
TL;DR: Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
References
More filters
Journal Article
Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes.
Journal ArticleDOI
The role of human papillomavirus in the increased incidence of base of tongue cancer
Per Attner,Juan Du,Anders Näsman,Lalle Hammarstedt,Torbjörn Ramqvist,Johan Lindholm,Linda Marklund,Tina Dalianis,Tina Dalianis,Eva Munck-Wikland +9 more
TL;DR: The incidence of base of tongue cancer, as well as the proportion of HPV‐positive tumors, has increased in Sweden during the study period, suggesting that HPV may contribute to this increase.
Nasopharyngeal carcinoma incidence and mortality in China in 2010
TL;DR: Wang et al. as discussed by the authors analyzed the NNasopharyngeal carcinoma (NPC) incidence and mortality data in some domestic cancer registries, and provided scientific information that can be harnessed for NPC control and prevention.
Journal ArticleDOI
Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China
Wei Hua Jia,Qi Hong Huang,Jian Liao,Weimin Ye,Yin Yao Shugart,Qing Liu,Li Zhen Chen,Yan Hua Li,Xiao Lin,Fa Lin Wen,Hans-Olov Adami,Yi Zeng,Yi Xin Zeng +12 more
TL;DR: There is great potential to work in the area of NPC prevention and treatment in southern China to decrease NPC risk and improve survival risk rates in order to reduce M:I ratios.
Journal ArticleDOI
Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent
Timothy R. Rebbeck,Susan S. Devesa,Baoli Chang,Clareann H. Bunker,Iona Cheng,Kathleen A. Cooney,Rosalind A. Eeles,Pedro L. Fernández,Veda N. Giri,Serigne Magueye Gueye,Christopher A. Haiman,Brian E. Henderson,Chris F. Heyns,Jennifer J. Hu,Sue A. Ingles,William B. Isaacs,Mohamed Jalloh,Esther M. John,Adam S. Kibel,LaCreis R. Kidd,Penelope Layne,Robin J. Leach,Christine Neslund-Dudas,Michael N. Okobia,Elaine A. Ostrander,Jong Y. Park,Alan L. Patrick,Catherine M. Phelan,Camille Ragin,Robin Roberts,Benjamin A. Rybicki,Janet L. Stanford,Sara S. Strom,Ian M. Thompson,John S. Witte,Jianfeng Xu,Edward D. Yeboah,Ann W. Hsing,Charnita Zeigler-Johnson +38 more
TL;DR: A higher proportion of T1 stage prostate tumors in countries with greater percent gross domestic product spent on health care and physicians per 100,000 persons reported lower mortality rates, suggesting that CaP is underdiagnosed and/or underreported in SSA men.